Heterocyclic Building Blocks-Naphthyridine

3-Bromo-1,5-naphthyridine, cas is 17965-71-8, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

To a solution of 3-bromo-l,5-naphthyridine (C-2) (4.181 g, 20.0 mmol, 1.0 eq ) in 1,4-dioxane (100 mL), tert-butylcarbamate (2.812 g, 24.0 mmol, 1.2 eq), cesium carbonate (9.132 g, 28.0 mmol, 1.4 eq), tris(benzylideneacetone)dipalladium (183 mg, 0.20 mmol, 0.01 eq) and Xantphos (347 mg, 0.60 mmol, 0.03 eq) were added. The mixture was heated at reflux for 16 h under an argon atmosphere. After the reaction mixture was cooled to RT, it was diluted with water (300 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (200 mL), dried over Na2S04 and filtered. The filtrate was concentrated in vacuo. The resultant residue was purified by silica gel column chromatography (15 – 25%o ethyl acetate- petroether) to afford the desired product, tert-butyl l,5-naphthyridin-3-ylcarbamate (D-12) (4.047 g, 82.5% yield) as a yellow oil. ‘H NMR (300 MHz, DMSO-17965-71-8, As the rapid development of chemical substances, we look forward to future research findings about 17965-71-8

Reference£º
Patent; INTELLIKINE, INC.; REN, Pingda; LIU, Yi; LI, Liansheng; CHAN, Katrina; WILSON, Troy, Edward; CAMPBELL, Simon, Fraser; WO2011/149937; (2011); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

6-Bromo-1,8-naphthyridin-2-ol, cas is 72754-05-3, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

72754-05-3, Example 7 Synthesis of boronic acid 7Reaction reagents and conditions: a. 1 ) NaH, THF, r.t.; 2) nBuLi, B(OiPr)3, -70C to 0C7.1 Boronic acid 7: To a solution of compound 6 (10 g, 44.44 mmol) in dry tetrahydrofuran (350 mL) was added sodium hydride(2 g, 66.66 mmol, 80% dispersion) at 0C. After the mixture was stirred at room temperature for 30 min, the mixture was cooled below -60C in a dry ice/acetone bath, and n- butyllithium (70 mL, 112 mmol, 1.6 M in hexane) was added over 30 min. The mixture was kept stirring for another 30 min, then triisopropyl borate (40 mL, 177 mmol) was added dropwise. The reaction mixture was stirred for 10 min, and then warmed to 0C slowly in an ice bath. HC1 (5 N) was added to the mixture to adjust pH = 3-4, and the mixture was stirred for 20 min. Aq. NaOH was added to the mixture to adjust pH = 10. After filtration, the organic layer was separated. The aqueous layer was extracted with a mixture of ethyl acetate/THF (4/1; 2 x 120 mL) and EtOAc (100 mL) . The aqueous layer was adjusted to pH = 5-6 with HC1. The precipitate thus formed was collected by filtration and dried to give boronic acid 7 (3.5 g, 41%) a white solid.

As the rapid development of chemical substances, we look forward to future research findings about 72754-05-3

Reference£º
Patent; OTSUKA PHARMACEUTICAL CO., LTD.; ABUDUSAIMI, Mamuti; YE, Fangguo; SUN, Jiangqin; MIYAMOTO, Hisashi; CHENG, Jay-Fei; OKA, Daisuke; WO2013/29548; (2013); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1569-16-0,2-Methyl[1,8]-Naphthyridine,as a common compound, the synthetic route is as follows.,1569-16-0

a 2-Methyl-8-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,8-naphthyridine A mixture of 2-methyl-1,8-naphthyridine (J. Chem. Soc. (C) 1966, 315; 5.13 g, 35.58 mmole), 10percent Pd/C (1.14 g, 1.07 mmole), and absolute EtOH (70 mL) was deoxygenated through three evacuation/H2 purge cycles, then was stirred briskly under a balloon of H2. After 18.5 hr, the mixture was filtered through celite.(R)., and the filter pad was washed sequentially with absolute EtOH and EtOAc. The filtrate was concentrated to dryness, and the residue was reconcentrated from EtOAc to leave an off-white solid (5.25 g). A solution of the above material (5.25 g), di-tert-butyl dicarbonate (15.53 g, 71.16 mmole), and CH2Cl2 (10 mL) was concentrated on the rotavap to remove the solvent, and the oily residue was heated under N2 in an oil bath set at 55-60¡ã C. After 45 hr, the reaction was cooled to RT, and the residue was flash chromatographed on silica gel (40percent EtOAc/hexanes). The title compound (4.90 g, 55percent) was obtained as a light yellow solid: 1H NMR (300 MHz, CDCl3) delta7.27 (d, J=7.6 Hz, 1H), 6.81 (d, 7.6 Hz, 1H), 3.69 -3.79 (m, 2H), 2.65-2.75 (m, 2H), 2.48 (s, 3H), 1.83-1.98 (m, 2H), 1.52 (s, 9H), MS (ES) m/e 249 (M+H)+.

1569-16-0 2-Methyl[1,8]-Naphthyridine 74073, anaphthyridine compound, is more and more widely used in various fields.

Reference£º
Patent; SmithKline Beecham Corporation; US6495560; (2002); B1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

1,8-Diazanaphthalene, cas is 254-60-4, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

Synthesis of 2-[1-(2-tert-butyl-6-chloro-5-methyl-pyrimidin-4-yl)-piperidin-4-yl]-[1,8]naphthyridine 20 ml of dimethylacetamide and 5 ml (17.8 mmoles) of diisopropylethylamine are added into a single-necked flask containing 1.5 g (6.84 mmoles) of 2-tert-butyl-4,6-dichloro-5-methyl-pyrimidine and 1.46 g (6.84 mmoles) of 2-piperidin-4-yl-[1,8]naphthyridine. This mixture is heated at 100 C. overnight. The next day 0.2 equivalent of naphthyridine is added and the mixture is heated for another 6 hours. The reaction mixture is returned to ambient temperature before concentrating to dryness. The residue obtained is taken up in a mixture of water, ethyl acetate and a saturated solution of sodium bicarbonate. The organic phase is separated and the aqueous phase reextracted with ethyl acetate. The collected organic phases are dried over magnesium sulphate then the solvent is evaporated off under reduced pressure (2 kPa). The residue is chromatographed on silica gel eluding with a gradient of heptane-ethyl acetate (70-30) to heptane-ethyl acetate (50-50). 1.77 g of expected product is obtained. TLC: Rf=0.50 [silica gel, eluent heptane-ethyl acetate (50-50). 1H-NMR (CDCl3): delta 1.37 (s, 9H, tert-butyl); 2.1 (m, 1H, cyclopropyl); 2.15 (m, 4H, N-CH2–CH–CH2); 2.27 (s, 3H, CH3); 3.1 and 4.05 (2m, 4H, CH2–N–CH2); 3.25 (m, 1H, N-CH2-CH2–CH2-CH2); [(7.48; 8.18; 9.12), 3m, 5H, naphthyridine]. MS: 396 (MH+).

254-60-4, As the rapid development of chemical substances, we look forward to future research findings about 254-60-4

Reference£º
Patent; Proskelia SAS; US2008/58348; (2008); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

15944-34-0, 7-Chloro-1,8-naphthyridin-2-ol is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,15944-34-0

A solution of 7-chloro-l,8-narhohthyridin-2(lH)-one rJ.Org.Chem. 1990, 55, 4744-4750] in dry DMF (20 mL) (540 mg, 3.0 mmol) at O0C was treated with sodium hydride (144 mg, 60% in mineral oil, -3.6 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was cooled using an ice bath. A solution of 2-{4-[(tert- butyoxycarbonyl)amino]piperidin-lyl} ethyl methanesulfonate in DMF (Intermediate 2), 0.33 mmol/ mL, 10 mL, ~3.3 mmol) was then added over 1 hour. The reaction was allowed to warm to room temperature and stirred overnight. It was diluted with water and extracted with dichloromethane (3 X 50 mL). The combined organic layers were washed with saturated sodium chloride solution (3 X 10 mL), dried over sodium sulfate and evaporated. Chromatography on silica gel using methanol in dichloromethane (0-15%) gave the title compound as a brown foam (711 mg, 58%). MS (ESV 407 (MH)+ for C20H27ClN4O31H NMR (CDClO delta ppm 1.42 (s, HH); 1.84-1.99 (m, 2H); 2.12-2.22 (m, IH); 2.22-2.37 (m, 2H); 2.66-2.80 (m, 2H); 3.03-3.19 (m, IH); 3.39-3.55 (m, IH); 4.34-4.48 (m, IH); 4.62 (t, 2H); 6.72 (d, IH); 7.15 (d, IH); 7.61 (d, IH); 7.78 (d, IH).

As the paragraph descriping shows that 15944-34-0 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2008/71964; (2008); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

1,6-Naphthyridine-2-carboxylic acid, cas is 197507-59-8, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

To a solution OF 4- [ (4-BROMOPHENYL) (ethoxyimino) methyl]-1- (4-methyl-4-piperidinyl)- piperidine (50mg, 0. 12MMOL), 1, 6-naphthyridine-2-carboxylic acid (25mg, 0. 14MMOL), Et3N (44 mg, 0. 43MMOL) in DMF (3 mL, anhydrous) was added HATU (60mg, 0. 16MMOL) at room temperature. After 16 h the reaction mixture was poured into ice water, and the solid was collected by filtration. The solid was dissolved in CH2CI2, and dried over NA2SO4. CONCENTRATION in vacuo, and purification by preparative TLC (CH2CI2-MEOH, 9: 1) afforded the title compound as a light yellow powder. MS: 564 (M+).

197507-59-8, As the rapid development of chemical substances, we look forward to future research findings about 197507-59-8

Reference£º
Patent; SCHERING AKTIENGESELLSCHAFT; WO2004/113323; (2004); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

337958-60-8, 5,7-Dichloro-1,6-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,337958-60-8

To a 40 mL vial was added 5,7-dichloro-1,6-naphthyridine, (510 mg, 2.56 mmol), tert-butyl (1R,3s,5S)-3 -amino-9-azabicyclo [3.3.1 jnonane-9-carboxylate (677 mg, 2.82 mmol), DIPEA (1.34 mL, 7.69 mmol), and DMSO (8.54 mL). The vial was capped and the reaction mixture was heated to 110 C and stirred for 16 h. The reaction mixture was5 diluted with water and brine and extracted with EtOAc (4 x 30 mL). The combined organic fractions were dried over sodium sulfate, filtered, and concentrated to afford the desired product as a brown solid which was dissolved in a minimal amount of DCM and adsorbed onto Celite, purified by column chromatography (40 g column; 0-100% EtOAc in hexanes) to afford the title product as a yellow solid (901.6 mg, 86 % yield; 9910 % purity). (m/z): [M+Hj calcd for C21H27C1N402 403.18, found 403.3.

As the paragraph descriping shows that 337958-60-8 is playing an increasingly important role.

Reference£º
Patent; THERAVANCE BIOPHARMA R&D IP, LLC; HUDSON, Ryan; KOZAK, Jennifer; FATHEREE, Paul R.; PODESTO, Dante D.; BRANDT, Gary E.L.; FLEURY, Melissa; BEAUSOLEIL, Anne-Marie; HUANG, Xiaojun; THALLADI, Venkat R.; (121 pag.)WO2016/191524; (2016); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

8-Chloro-3-methoxy-1,5-naphthyridine, cas is 952059-69-7, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

952059-69-7, General procedure: (Method C2) Synthesis of 4-(4-tert-butylphenyl)-N-(4-(7-methoxy-1,5-naphthyridin-4-yloxy)phenyl)phthalazin-1-amine In a nitrogen purged sealed tube, 8-chloro-3-methoxy-1,5-naphthyridine (0.053 g, 0.271 mmol) was dissolved in DMF (2.00 mL). 4-(4-(4-Tert-butylphenyl)phthalazin-1-ylamino)phenol (0.100 g, 0.271 mmol) and cesium carbonate (0.176 g, 0.541 mumol) were added, and the mixture in the tube was stirred at 90 C. for 17 h. Upon cooling to RT, the mixture was concentrated in vacuo, and purified by silica gel chromatography using 0-100% CH2Cl2:MeOH(90:10)/CH2Cl2 to yield 4-(4-tert-butylphenyl)-N-(4-(7-methoxy-1,5-naphthyridin-4-yloxy)phenyl)phthalazin-1-amine as off-white solid. MS [M+H]=528.1; Calc’d 527.6 for C33H29N5O2.

As the rapid development of chemical substances, we look forward to future research findings about 952059-69-7

Reference£º
Patent; CEE, Victor J.; DEAK, Holly L.; DU, Bingfan; GEUNS-MEYER, Stephanie D.; HUA, Zihao; MARTIN, Matthew W.; MARX, Isaac; NGUYEN, Hanh Nho; OLIVIERI, Philip R.; PANTER FABER, Kathleen; ROMERO, Karina; SCHENKEL, Laurie; WHITE, Ryan; US2014/336182; (2014); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

1,5-Naphthyridine, cas is 254-79-5, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

1,5-naphthyridine (111.6 g, 0.85 mol) was dissolved in acetic acid (1000 mL), sodium acetate (140.9 g, 1.72 mol) was added and heated to 80 C.A solution of bromine (153 g, 0.96 mol) in 150 mL was added dropwise thereto, maintaining the temperature of the reaction mixture at 80 C – 90 C, and the reaction was completed at 85 C for 3 h.After cooling, the reaction solution was spun and H2O (1000 mL) was added.The mixture was made alkaline with 50% aqueous sodium hydroxide solution, stirred for 30 min, suction filtered, and the filter cake was washed with water and dried.Crude product added to ethyl acetate (1600 mL)Heated to reflux for 3 h.After cooling to room temperature, filtration, the filter cake was washed with ethyl acetate and dried to give 3,7-dibromo-1,5-naphthyridine.The filtrate was spun dry to give a crude 3-bromo naphthyridine (84 g, white yellow solid, yield 47%).Purification by petroleum ether: ethyl acetate = 20:1 – 10:1 yielded pure 3-bromonaphthalene (67 g, white solid, yield 37%).

254-79-5, As the rapid development of chemical substances, we look forward to future research findings about 254-79-5

Reference£º
Patent; Suzhou Kangrun Pharmaceutical Co., Ltd.; Jin Haowen; Xu Weiliang; Xu Weizheng; (8 pag.)CN108658977; (2018); A;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

5912-35-6, 6-Amino-8-bromo-1,7-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5912-35-6, To a stirred solution of 8-BROMO- [1, 7] naphthyridin-6-ylamine (1.70 g) in a mixture of toluene (7 ml), DMF (11 ml) and aqueous K2CO3 (2.31 g in 5 ml water) is added bis (dibenzylideneacetone) palladium (174 mg), triphenylphosphine (158 mg) and 5-fluoro-2- methoxyphenylboronic acid (1.38 g). The mixture is stirred for 3.5 hours at 100C, then diluted with ethyl acetate and filtered through Celite. The ethyl acetate solution is washed with 2N NAOH and water, dried over magnesium sulphate, then concentrated to afford the title compound. MS: APCI 270.0 MH+.

As the paragraph descriping shows that 5912-35-6 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2004/55013; (2004); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem